BPIQ Blog

In case you missed our posts on Linked-In and Twitter yesterday, the Wall Street Journal is reporting big news in gene therapy and...

An important readout occurred today in the very hot pharmaceutical development area called NASH, a severe fatty liver disease. NASH is...

We are thrilled to report that our Amp Core hypothetical fund is off to a tremendous start in 2019. This fund is up around 13% since the...

Summary CARA's switch from pain to pruritis (chronic severe itching) is a sound strategy as the pruritis data and market provide a much...

Download Full Article Summary Amarin has patent protection for Vascepa® out to 2030, including protection related to the possible...

10/31/18 Amp cut its positions in ALKS in various AMP funds today by 1/2 after careful review of FDA briefing document for tomorrow's FDA...

ASH abstracts coming 12/1. Looking forward to $ARQL update on reversible Btk inhib ARQ 531 for C481S mutants (Ibrutinib resistance) in B...

SEL-212 data looks good thru 5 months, and therapy appears more likely approvable with future phase 3 trial, but data not exceptional...

Amp funds are invested in a small percentage in CLSD currently (as of 10/6/18). We like the next-gen ocular steroid platform and the...

John McCain died of glioblastoma last month. My father died of glioblastoma back in the 1970s when he was around 40 years old. Currently,...

Yesterday, Amarin (AMRN) reported top-line results from a landmark Phase 3 study which showed that their product called Vascepa reduced...

Looking at available information, it is likely that FOMX will read out its pivotal repeat phase 3 trial of FMX101 for acne some time...

Amp's exciting news, and best upcoming biotech picks

Summary TBPH reporting TD-9855 data in nOH by end of July Medium risk and reward opportunity TBPH July data for wholly owned TD-9855...

Second Phase 3 study of ZX008 in Dravet's met primary and all key second endpoints. Data for ZX008 in Dravet continues to look very good...

First efficacy data readout coming on July 18, 2018 for MarzAA. High risk event, but encouraging that press release indicates...

Zogenix (ZGNX) is set to imminently release additional phase 3 data from its trial with its drug ZX008 (low dose fenfluramine) for...

Looking forward to Global Blood Therapeutics report out of Part A from their Phase 3 Hope study of their drug voxelotor (formerly GBT440)...

Congrats Array Biopharma on continued excellent data on its colorectal cancer (CRC) study of patients with BRAF V600E mutations with the...

It will be an exciting rest of June for Array Biopharma (ARRY) with 2 PDUFAs (final FDA drug approvals) for its 2 lead drug candidates...